Stocks · News reference

Piper Sandler Maintains Overweight on Abivax, Raises Price Target to $175

Jul 9, 2026, 3:59 PMBenzinga Newsdesk

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 9, 2026, 3:59 PM
Checked: Jul 9, 2026, 4:05 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaJul 30, 2026, 8:19 PMBenzinga Newsdesk
Abivax Completes Pre-New Drug Application Interaction For Obefazimod With FDA To Treat Adults With Moderately To Severely Active Ulcerative Colitis
Read original at benzinga
ABVX PARIS:FR
BenzingaJul 23, 2026, 6:06 PMVandana Singh
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis
Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.
Read original at benzinga
ABVX AMGN JNJ MRK PALI
BenzingaJul 17, 2026, 6:04 PMBenzinga Newsdesk
'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La Lettre
https://www.lalettre.fr/fr/english-corner/2026/07/17/biotech-abivax-re-engages-investment-bank-centerview-for-big-pharma-takeover-talks,110842674-gra
Read original at benzinga
ABVX AZN LLY